I’m in Hobart attending meetings prior to the Alzheimer’s Australia 15th National Conference, and last night the dinner was half sponsored by Souvenaid® Australia. Someone referred me to this product earlier this year, and because I don’t have AD but another type of dementia, I had not followed it up. It was referred to at the Alzheimer’s Disease International conference in Taipei in April this year by one of the medical researchers; Alzheimer’s Australia have this fact sheet on their website Souvenaid Q & A. If you have AD, you will want to investigate it further. Souvenaid is the result of research by investigators from MIT, and other international groups being conducted since 2002, and was developed in Amsterdam by Advanced Medical Nutrition division of Nutricia. I could not find a website for a supplier in Europe, but you will find more information at Souvenaid®, Souvenaid® UK and Souvenaid® US.
What is Souvenaid®?
A new nutritional approach to Alzheimer’s disease
Souvenaid® is a new medical nutrition drink that nutritionally supports memory function in the early stages of Alzheimer’s disease. Taken once daily, Souvenaid® has been shown to have a positive effect in people during the early stages of the disease, by nutritionally supporting the connections in the brain, called synapses.
Based on more than 10 years of research and development, Souvenaid® contains a unique combination of nutrients, called FortasynTM Connect, which provide the nutritional building blocks that are required by people with early Alzheimer’s disease.
The unique combination of nutrients in Souvenaid® includes omega-3 polyunsaturated fatty acids, uridine monophosphate and choline, together with phospholipids, B vitamins and other nutrients, at levels difficult to achieve from dietary intake alone. Click the button below to see what you would have to eat, on top of your normal diet, to obtain the same levels of nutrients that one 125ml bottle of Souvenaid® provides.
Souvenaid® is a Food for Special Medical Purposes for the dietary management of the early stages of Alzheimer’s disease and must be used under medical supervision. Consult with your doctor, nurse or pharmacist for advice.